Keyphrases
Randomized Controlled Trial
100%
Escitalopram
100%
Normal Brain
100%
Postsynaptic Density Protein 95 (PSD-95)
100%
Selective Serotonin Reuptake Inhibitors
83%
Synaptic Vesicle Protein 2A (SV2A)
50%
Mechanism of Action
33%
Synaptic Plasticity
33%
Neuroplasticity
33%
UCB-J
33%
Psychiatric Disorders
16%
Healthy Individuals
16%
Treatment Response
16%
Hippocampus
16%
Placebo
16%
Neocortex
16%
Placebo-controlled Study
16%
Daily Intake
16%
Arterial Input Function
16%
Treatment Delay
16%
Healthy Participants
16%
Group Differences
16%
Neuropsychiatric Disorders
16%
Time Effect
16%
PET Scan
16%
Biological Explanations
16%
In Vivo Evidence
16%
Neuropharmacological Effect
16%
Oral Dosing
16%
Cognitive Disorders
16%
Human Following
16%
J-PET
16%
Neuroscience
Randomized Controlled Trial
100%
Escitalopram
100%
Selective Serotonin Reuptake Inhibitor
83%
Synaptic Vesicle
50%
Beta1 Integrin
50%
Placebo
33%
Neuroplasticity
33%
Synaptic Plasticity
33%
Positron Emission Tomography
16%
In Vivo
16%
Hippocampus
16%
Cognitive Disorders
16%